Outcome of Unrelated Umbilical Cord Blood Transplantation in India: A Less Explored Horizon.
[OBJECTIVE] There is dearth of clinical data from India regarding outcomes of umbilical cord blood transplant (UCBT).
APA
Mohapatra D, Bakhshi S, et al. (2025). Outcome of Unrelated Umbilical Cord Blood Transplantation in India: A Less Explored Horizon.. Indian pediatrics, 62(12), 881-885. https://doi.org/10.1007/s13312-025-00143-0
MLA
Mohapatra D, et al.. "Outcome of Unrelated Umbilical Cord Blood Transplantation in India: A Less Explored Horizon.." Indian pediatrics, vol. 62, no. 12, 2025, pp. 881-885.
PMID
40728782
Abstract
[OBJECTIVE] There is dearth of clinical data from India regarding outcomes of umbilical cord blood transplant (UCBT). This study aimed to analyze the long-term outcomes in children who underwent UCBT at a single Indian center.
[METHODS] This retrospective study included patients who underwent UCBT between 2011 and 2024 in a tertiary care center in Northern India. Data on HLA-matching, cell dose, conditioning, engraftment, toxicities and survival outcomes were recorded.
[RESULTS] Out of 20 patients with median (Q1, Q3) age 4 (2, 6) years, 11 had leukemia and 9 had immunodeficiencies or enzymopathies. Majority (90%) received myeloablative-conditioning. Median CD34 + cell dose and total nucleated-cell dose were 3.3 × 10/kg, and 9.6 × 10/kg, respectively, with median (Q1, Q3) time for neutrophil engraftment of 28.5 (23, 36) days. The disease-free-survival (DFS) was 40.3, 77.8 and 10.2% in the overall cohort, benign- and malignant-cohorts, respectively, with 20% transplant-related mortality.
[CONCLUSIONS] Umbilical cord blood-transplant showed good outcomes in non-malignant diseases in the absence of matched-related-donors, while, for malignancies, outcomes were suboptimal compared to global figures.
[METHODS] This retrospective study included patients who underwent UCBT between 2011 and 2024 in a tertiary care center in Northern India. Data on HLA-matching, cell dose, conditioning, engraftment, toxicities and survival outcomes were recorded.
[RESULTS] Out of 20 patients with median (Q1, Q3) age 4 (2, 6) years, 11 had leukemia and 9 had immunodeficiencies or enzymopathies. Majority (90%) received myeloablative-conditioning. Median CD34 + cell dose and total nucleated-cell dose were 3.3 × 10/kg, and 9.6 × 10/kg, respectively, with median (Q1, Q3) time for neutrophil engraftment of 28.5 (23, 36) days. The disease-free-survival (DFS) was 40.3, 77.8 and 10.2% in the overall cohort, benign- and malignant-cohorts, respectively, with 20% transplant-related mortality.
[CONCLUSIONS] Umbilical cord blood-transplant showed good outcomes in non-malignant diseases in the absence of matched-related-donors, while, for malignancies, outcomes were suboptimal compared to global figures.
MeSH Terms
Humans; India; Cord Blood Stem Cell Transplantation; Child, Preschool; Retrospective Studies; Male; Female; Child; Treatment Outcome; Infant; Transplantation Conditioning